Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s):  MEDXF

Healthcare Drug Manufacturers - Specialty & Generic
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation... see more

Current News (TSX:MDP)

Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation

Newsfile April 15, 2026

Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection

Newsfile February 11, 2026

Medexus Schedules Third Fiscal Quarter 2026 Conference Call

Newsfile February 3, 2026

Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares

Newsfile November 20, 2025

Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares

Newsfile November 17, 2025

Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection

Newsfile November 12, 2025

Medexus Schedules Second Fiscal Quarter 2026 Conference Call

Newsfile November 4, 2025

Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors

Newsfile September 25, 2025

Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection

Newsfile August 12, 2025
View More News ››

Opinion & Analysis (TSX:MDP)

VIDEO: Focused on Children's Medicine in an Underserved Market

BTV-Business Television June 8, 2016

Pediapharm (V.PDP) is a very attractive takeover candidate, Stockhouse poster says

Stockhouse Editorial April 20, 2015
View More Opinion ››

Bullboard Posts (TSX:MDP)

Bullish wedge formed

The chart is forming a beautiful bullish wedge. Once tax-loss sellers are done, we might see a pop. It depends on the general market to...
cleareye - December 18, 2025

smallcapdiscoveries.com interview

https://www.youtube.com/watch?v=oTkppTgGhd4
Possibleidiot01 - March 19, 2025

RE:Assessment

I screened these guys the other day. Look attractively valued for what's ahead this year. Started a position.
MintyZyn - March 10, 2025

Assessment

20% below the financing level + this = just opened a small position. GLTA Would welcome your analysis on this small cap. It has recently...
retiredcf - February 10, 2025

$4 financing

Houston, we have a problem?
thedave2006 - February 6, 2025

FDA Approval of GRAFAPEX, 100m rev projected~5yr

https://ca.finance.yahoo.com/news/medexus-announces-fda-approval-grafapex-155900222.html
SushiGobbler - January 23, 2025
View more Bullboard ››

MindBio Therapeutics Corp.

MindBio Therapeutics Corp.

MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic ...
View More »

Podcasts